Averna Therapeutics
Genomic Medicines that Insert Therapeutic Genes into Safe Harbors Within the DNA
Company Overview
Snapshot
Founded in January 2022, Averna Therapeutics operates with 51–200 employees. The company has raised $82 million across one funding round from 10 investors, with Delos Capital and Novartis Venture Fund leading the Series A round. In June 2024, the company launched with its Series A financing to develop redosable genomic medicines.
Business overview
Averna Therapeutics is a biotechnology company focused on developing genomic medicines to treat a wide range of diseases, including genetic disorders, cancer, and autoimmune conditions. The company's core technology involves inserting therapeutic genetic instructions into specific "safe harbor" regions of the genome, ensuring stable gene integration without disrupting normal cellular functions. By encoding medicines in RNA, Averna utilizes validated, non-viral delivery platforms designed for safety, efficiency, scalability, and cost-effectiveness, aiming for curative outcomes through redosing. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development markets.
Strategic signal
In January 2025, former Moderna CMO Tal Zaks discussed Averna Therapeutics' focus on rare genetic diseases through gene editing, highlighting the company's groundbreaking drug development. This signals a strong strategic direction towards addressing significant unmet medical needs and leveraging advanced gene editing techniques, positioning Averna Therapeutics as a key player in the future of genomic medicine.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent funding event for Averna Therapeutics?
- In June 2024, Averna Therapeutics launched with an $82 million Series A financing round, led by.
- What is Averna Therapeutics' primary focus?
- Averna Therapeutics specializes in developing genomic medicines that insert therapeutic genes into safe harbor regions within the DNA to treat genetic disorders, cancer, and autoimmune conditions.
- Which investors participated in Averna Therapeutics' Series A funding round?
- The Series A funding round for Averna Therapeutics included investments from.
- What is the strategic significance of Tal Zaks' involvement with Averna Therapeutics?
- In January 2025, former Moderna CMO Tal Zaks discussed Averna Therapeutics' work on gene editing for rare genetic diseases, underscoring the company's ambition to develop groundbreaking drugs and its potential impact on the biotechnology landscape.